Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants.

MLA

Arachchillage, Deepa R. J., et al. “Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid Syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): Use of Direct Acting Oral Anticoagulants.” British Journal of Haematology, vol. 189, no. 2, Apr. 2020, pp. 212–15. EBSCOhost, https://doi.org/10.1111/bjh.16308.

APA

Arachchillage, D. R. J., Gomez, K., Alikhan, R., Anderson, J. A. M., Lester, W., & Laffan, M. (2020). Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants. British Journal of Haematology, 189(2), 212–215. https://doi.org/10.1111/bjh.16308

Chicago

Arachchillage, Deepa R J, Keith Gomez, Raza Alikhan, Julia A M Anderson, Will Lester, and Mike Laffan. 2020. “Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid Syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): Use of Direct Acting Oral Anticoagulants.” British Journal of Haematology 189 (2): 212–15. doi:10.1111/bjh.16308.